The Effect of Vinegar on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes

The Effect of Vinegar on Glucose and Lipid Metabolism in Peripheral Tissues in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02309424

Enrollment

Registered

2014-12-05

Start date

2008-07-31

Completion date

2014-12-31

Last updated

2014-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

This open, randomized, cross-over, placebo-controlled study aims to investigate the effects of vinegar on glucose metabolism, endothelial function and circulating lipid levels in subjects with impaired glucose tolerance or type 2 diabetes, using the arteriovenous difference technique.

Detailed description

Subjects with IGT or type 2 diabetes will be randomised to consume 20ml vinegar (6% acetic acid) or placebo before a mixed meal. Plasma samples will be taken for 300min from the radial artery and from a forearm vein for measurements of glucose, insulin, triglycerides, non-esterified fatty acids (NEFA) and glycerol. Muscle blood flow will be measured with strain-gauge plethysmography. Glucose flux will be calculated as the arteriovenous difference of glucose multiplied by the blood flow rates.

Interventions

DIETARY_SUPPLEMENTVinegar

0,50mmol vinegar (6% acetic acid)

OTHERPlacebo

50 ml water

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Subjects with impaired glucose tolerance or newly diagnosed type 2 diabetes before the initiation of medication therapy 2. Recreationally active 3. With stable body weight and diet during the last two months.

Exclusion criteria

1. Any systemic disease (besides glucose abnormalities) 2. Any medication therapy 3. Diabetic complications

Design outcomes

Primary

Measure	Time frame
Muscle glucose uptake following meal ingestion (area under the glucose uptake versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal

Secondary

Measure	Time frame
Plasma insulin levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma triglyceride levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma NEFA levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma glucose levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Muscle blood flow following meal ingestion (area under the blood flow rates versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Number of participants with adverse events	300 min postmeal
Plasma glycerol levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026